Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)

被引:0
|
作者
Simpkins, Fiona
Nasioudis, Dimitrios
Wethington, Stephanie L.
Martin, Lainie P.
Tanyi, Janos Laszlo
Latif, Nawar A.
Torigian, Drew A.
Omran, Dalia K.
Rodriguez, Diego
Smith, Simon
Dean, Emma
Domchek, Susan M.
Drapkin, Ronny
Shih, Ie-Ming
Brown, Eric J.
Hwang, Wei-Ting
Armstrong, Deborah Kay
Gaillard, Stephanie
Giuntoli, Robert Lawrence, II
Liu, Joyce F.
机构
[1] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Univ Penn, Dept Radiol, Philadelphia, PA USA
[4] AstraZeneca, R&D Oncol, Royston, England
[5] AstraZeneca, R&D Oncol, Cambridge, England
[6] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
[7] Univ Penn, Dept Canc Biol, Philadelphia, PA USA
[8] Univ Penn, Abramson Family Canc Res Inst, Perelman Sch Med, Philadelphia, PA USA
[9] Dana Farber Canc Inst, Boston, MA USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
5510
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
    Shah, Payal D.
    Wethington, Stephanie L.
    Pagan, Cheyenne
    Latif, Nawar
    Tanyi, Janos
    Martin, Lainie P.
    Morgan, Mark
    Burger, Robert A.
    Haggerty, Ashley
    Zarrin, Haley
    Rodriguez, Diego
    Domchek, Susan
    Drapkin, Ronny
    Shih, Ie-Ming
    Smith, Simon A.
    Dean, Emma
    Gaillard, Stephanie
    Armstrong, Deborah
    Torigian, Drew A.
    Hwang, Wei-Ting
    Giuntoli, Robert
    Simpkins, Fiona
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 246 - 253
  • [2] Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor- Resistant Homologous Recombination-Deficient Ovarian Cancer
    Wethington, Stephanie L.
    Shah, Payal D.
    Martin, Lainie
    Tanyi, Janos L.
    Latif, Nawar
    Morgan, Mark
    Torigian, Drew A.
    Rodriguez, Diego
    Smith, Simon A.
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei -Ting
    Armstrong, Deborah K.
    Gaillard, Stephanie
    Giuntoli, Robert
    Simpkins, Fiona
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (15) : 2800 - 2807
  • [3] Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer.
    Shah, Payal D.
    Zarrin, Haley
    Wethington, Stephanie
    Latif, Nawar
    Martin, Lainie
    Rodriguez, Diego
    Elkins, Katie
    Giuntoli, Robert
    Burger, Robert
    Tanyi, Janos
    Morgan, Mark
    Domchek, Susan M.
    Gailliard, Stephanie
    Armstrong, Deborah K.
    Simpkins, Fiona
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (13) : 75 - 75
  • [4] A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
    Liu, Joyce
    Barry, William Thomas
    Birrer, Michael J.
    Lee, Jung-Min
    Buckanovich, Ronald J.
    Fleming, Gini F.
    Rime, Bj
    Buss, Mary K.
    Natiam, Sreenivasa R.
    Hurteau, Jean
    Luo, Weixiu
    Quy, Philippa
    Obermayer, Elizabeth
    Whalen, Christin
    Lee, Hang
    Winer, Eric P.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18)
  • [5] Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
    Liu, Joyce F.
    Barry, William T.
    Birrer, Michael
    Lee, Jung-Min
    Buckanovich, Ronald J.
    Fleming, Gini F.
    Rimel, B. J.
    Buss, Mary K.
    Nattam, Sreenivasa
    Hurteau, Jean
    Luo, Weixiu
    Quy, Philippa
    Whalen, Christin
    Obermayer, Lisa
    Lee, Hang
    Winer, Eric P.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula A.
    [J]. LANCET ONCOLOGY, 2014, 15 (11): : 1207 - 1214
  • [6] Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
    Wethington, Stephanie L.
    Shah, Payal D.
    Martin, Lainie P.
    Tanyi, Janos Laszlo
    Latif, Nawar A.
    Morgan, Mark Aloysuis
    Torigian, Drew A.
    Pagan, Cheyenne
    Rodriguez, Diego
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Le-Ming
    Smith, Simon
    Dean, Emma
    Armstrong, Deborah Kay
    Gaillard, Stephanie
    Simpkins, Fiona
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naive Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
    Drew, Yvette
    Kim, Jae-Weon
    Penson, Richard T.
    O'Malley, David M.
    Parkinson, Christine
    Roxburgh, Patricia
    Plummer, Ruth
    Im, Seock-Ah
    Imbimbo, Martina
    Ferguson, Michelle
    Rosengarten, Ora
    Steeghs, Neeltje
    Kim, Min Hwan
    Gal-Yam, Einav
    Tsoref, Daliah
    Kim, Jae-Hoon
    You, Benoit
    De Jonge, Maja
    Lalisang, Roy
    Gort, Eelke
    Bastian, Sara
    Meyer, Kassondra
    Feeney, Laura
    Baker, Nigel
    Ah-See, Mei-Lin
    Domchek, Susan M.
    Banerjee, Susana
    [J]. CLINICAL CANCER RESEARCH, 2024, 30 (01) : 50 - 62
  • [8] OREO PHASE IIIB TRIAL: OLAPARIB MAINTENANCE RETREATMENT IN PLATINUM-SENSITIVE, RELAPSED EPITHELIAL OVARIAN CANCER PATIENTS PREVIOUSLY TREATED WITH A PARP INHIBITOR (PARPI)
    Pujade-Lauraine, E.
    Colombo, N.
    Glasspool, R.
    Asselain, B.
    Huzarski, T.
    Korach, J.
    Marme, F.
    Mirza, M. R.
    Redondo, A.
    Scambia, G.
    Blakeley, C.
    Milner, A.
    Selle, F.
    Vergote, I.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1634 - 1635
  • [9] Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer
    Meteran, Hanieh
    Knudsen, Anja Or
    Jorgensen, Trine Lembrecht
    Nielsen, Dorte
    Herrstedt, Jorn
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [10] Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
    Oza, Amit M.
    Cibula, David
    Oaknin Benzaquen, Ana
    Poole, Christopher
    Mathijssen, Ron H. J.
    Sonke, Gabe S.
    Colombo, Nicoletta
    Spacek, Jiri
    Vuylsteke, Peter
    Hirte, Holger
    Mahner, Sven
    Plante, Marie
    Schmalfeldt, Barbara
    Mackay, Helen
    Rowbottom, Jacqui
    Lowe, Elizabeth S.
    Dougherty, Brian
    Barrett, J. Carl
    Friedlander, Michael
    [J]. LANCET ONCOLOGY, 2015, 16 (01): : 87 - 97